Medpace/$MEDP

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Medpace

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Ticker

$MEDP
Primary listing

Industry

Life Sciences Tools and Services

Employees

6,000

Medpace Metrics

BasicAdvanced
$13B
33.67
$13.46
1.47
-

What the Analysts think about Medpace

Analyst ratings (Buy, Hold, Sell) for Medpace stock.

Bulls say / Bears say

Medpace reported a 7.7% increase in Q4 2024 revenue to $536.6 million, indicating strong financial performance. (Medpace Holdings, Inc.)
The company achieved a 49.4% surge in Q4 2024 net income to $117.0 million, reflecting improved profitability. (GuruFocus)
Medpace expanded its share repurchase program by $600 million, demonstrating confidence in its financial health and commitment to shareholder value. (GuruFocus)
Ongoing securities law investigations could lead to legal and financial repercussions, potentially affecting shareholder value. (Monexa)
In Q1 2025, Medpace reported a net book-to-bill ratio of 0.90, indicating a decline in net new business awards and potential future revenue challenges. (GuruFocus)
The company's stock is currently rated as a 'Hold,' suggesting limited immediate upside potential. (GuruFocus)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.

Medpace Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Medpace Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MEDP

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs